JW Pharmaceutical Corporation

As of June 30, 2026, JW Pharmaceutical Corporation carries a market capitalization of 579.52B, placing it among publicly traded companies globally. Its enterprise value stands at 553.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

JW Pharmaceutical Corporation's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, JW Pharmaceutical Corporation has 22.55M shares outstanding.

As of June 30, 2026, JW Pharmaceutical Corporation trades at a trailing price-to-earnings ratio of 5.93. The price-to-sales ratio is 0.73, and the price-to-book ratio stands at 1.43.

As of June 30, 2026, JW Pharmaceutical Corporation trades at an EV/EBITDA multiple of 4.13 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.84 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. JW Pharmaceutical Corporation trades at an EV/FCF ratio of 5.53, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 553.23B versus a market cap of 579.52B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, JW Pharmaceutical Corporation maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, JW Pharmaceutical Corporation posted a return on equity (ROE) of 27.93, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 23.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 16.21, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 22.62, useful for judging operating efficiency across full business cycles. The company generates approximately 742.02M in revenue per employee across its workforce of 1,106.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.74 indicates how many times JW Pharmaceutical Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, JW Pharmaceutical Corporation recorded 14.02B in income tax expense. That works out to an effective tax rate of 12.16, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 115.30B, leaving 101.28B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, JW Pharmaceutical Corporation's stock has gained approximately 3.91% over the past 52 weeks. The 50-day moving average sits at 26,807.00, while the 200-day moving average is 28,384.25.

Over the twelve months ended June 30, 2026, JW Pharmaceutical Corporation generated 820.86B in revenue and converted that into 101.28B in net income, yielding earnings per share of 4,336.32. EBITDA reached 133.89B, while operating income came in at 114.40B.

As of June 30, 2026, JW Pharmaceutical Corporation holds 102.08B in cash and equivalents against 71.75B in total debt, resulting in a net debt position of 5.96B. Total book value stands at 405.90B, with working capital of 123.86B providing operational flexibility.

JW Pharmaceutical Corporation produced 134.48B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -34.38B in capital expenditures, free cash flow totaled 100.10B - equivalent to 4,285.82 per share.

Over the twelve months ended June 30, 2026, JW Pharmaceutical Corporation posted a gross margin of 47.29, reflecting its pricing power and cost economics. The operating margin of 13.94 and net profit margin of 12.34 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, JW Pharmaceutical Corporation paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 16.68, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.31, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to JW Pharmaceutical Corporation shareholders.

JW Pharmaceutical Corporation's most recent stock split took place on December 27, 2023 with a 50:51 split ratio.

As of June 30, 2026, JW Pharmaceutical Corporation has an Altman Z-Score of 4.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.